Skin cancers are by far the most common malignancies in fair-skinned populations, with an incidence now reaching epidemic proportions ([@bib29]; [@bib42]). There are ∼700 000 cases of cutaneous squamous cell carcinoma (cSCC) diagnosed each year in the United States and the frequency is rising worldwide ([@bib7]; [@bib12]). While the overall survival of patients with cSCC is high, these tumours are associated with considerable morbidity and pose a substantial financial burden for health-care systems. When cSCC metastasises, the prognosis is poor, with a 5-year survival rate of \<25% ([@bib43]; [@bib26]). Immunosuppressed patients such as organ transplant recipients (OTRs) and individuals with chronic lymphocytic leukaemia are at significantly increased risk for cSCC and are prone to multiple and often aggressive tumours ([@bib11]; [@bib20], [@bib19]).

An estimated 65% of cSCC arise from precursor lesions termed actinic keratoses (AKs) ([@bib6]). Actinic keratosis is associated with epidermal atypia and is thought to represent a continuum of progression from dysplastic keratinocytes to cSCC. Actinic keratoses affect up to 18% of people in the United Kingdom over 60 years of age, rising to 64% in Australia ([@bib13]; [@bib30]). They are the strongest independent risk factor for cSCC development, and often present as multiple lesions, producing 'field cancerisation\' if confluent. The precise rate of progression is unknown, however, a study from the United States that prospectively followed 169 patients with a total of 7784 AK estimated the risk of progression for an individual lesion was 2.57% at 4 years ([@bib6]). Evidence for progression of AK to cSCC is also provided by genetic studies that report AKs have a similar karyotypic profile to cSCC, but display a reduced degree of complexity, consistent with an earlier stage of tumour development ([@bib2]).

Despite the frequency of cSCC, their underlying molecular pathogenesis is poorly characterised, especially the changes involved in progression from AK to cSCC. Recent exome-level sequencing of cSCC revealed a huge mutational burden of ∼1 per 30 000 base pairs of coding sequence ([@bib9]). This makes cSCC the most highly mutated human malignancy, compounding the difficulty in defining 'driver\' molecular events underlying their development. Evidence to date supports important tumour suppressor roles for *TP53* and *NOTCH*, but the contribution of additional genes and pathways is unclear ([@bib9]; [@bib49]). Earlier studies demonstrated considerable karyotypic complexity in cSCC, with frequent gains on chromosomes 3q, 8q and 20q and losses of 3p, 4p, 9p, 13q, 17p and 17q ([@bib39]; [@bib35]; [@bib2]; [@bib5]; [@bib38], [@bib37]). Our previous genome-wide analysis using single-nucleotide polymorphism (SNP) microarrays revealed that well-differentiated (WD) tumours display a distinct genetic profile from moderately (MD) and poorly differentiated (PD) tumours, indicating that these may represent a separate subgroup of cSCC ([@bib37]). However, current published expression microarray studies have failed to corroborate this at the level of gene expression and have yielded little consensus on the genes that are differentially expressed in cSCC ([@bib48]). This can be largely attributed to small sample sizes, non-microdissected tumour specimens and the absence of correlation with cSCC grade among the tumours analysed ([@bib16]; [@bib25]; [@bib32]).

The purpose of our study was to identify potential 'drivers\' in the transition from AK to cSCC by comparing the transcriptome of tumour cells isolated by laser capture microdissection from cSCC, with that of dysplastic keratinocytes from AKs. We have identified a series of differentially expressed genes (DEGs) in cSCC and have demonstrated key biological processes that distinguish cSCC from AK. Furthermore, an enrichment of DEGs has been demonstrated in key pathways such as the mitogen activated protein kinase (MAPK) pathway, implicating this pathway in the evolution of cSCC from precursor lesions.

Materials and methods
=====================

Tumour samples
--------------

Fresh-frozen biopsies of normal skin, AK and cSCC were obtained at the time of surgical excision and immediately snap-frozen in liquid nitrogen. All patients provided informed consent in accordance with ethical approval from the East London and City Health Authority local ethics committee. For microarray analysis, patient material was preferentially included where matched AK and cSCC lesions were available from the same patient. Subsequent samples were chosen to represent a range of histological diagnoses from both immunosuppressed and immunocompetent patients. In total, 10 AKs and 30 primary cSCC (9 matched to AK) were analysed. The cSCC comprised 15 WD, 9 MD (including 1 cSCC admixed with an additional WD component, W-MD) and 6 PD (including 4 cSCC admixed with an MD component, M-PD). The samples were derived from 10 immunocompetent patients, 20 OTRs and 1 patient with chronic lymphocytic leukaemia, reflecting the spectrum of patients presenting with cSCC to our institution. Patient and sample characteristics are detailed in [Table 1](#tbl1){ref-type="table"}.

Expression microarray analysis
------------------------------

Laser capture microdissection and RNA extraction were performed as previously described ([@bib27]), such that all samples were estimated to be a minimum 90% enrichment for tumour or dysplastic cells. RNA quality and concentration was measured using the Agilent Bioanalyser (Agilent, Berkshire, UK). Ten nanograms of RNA was used as a template for whole transcriptome amplification and cDNA synthesis using the NuGen WT-ovation Pico RNA Amplification System according to the manufacturer\'s instructions (NuGen, San Carlos, CA, USA). Five micrograms of amplified cDNA was labelled with the FL-ovation Biotin Kit (NuGen) and hybridised to the Affymetrix HGU133 Plus 2.0 microarrays (Affymetrix, Santa Clara, CA, USA), comprising 54 675 features. All procedures were performed according to the manufacturer\'s recommended protocol. Raw data for all samples are available through the Gene Expression Omnibus (GEO: <http://www.ncbi.nlm.nih.gov/geo/>), accession number GSE45216.

Statistical analysis
--------------------

Quality control analysis was performed as recommended for Affymetrix microarrays using the R/Bioconductor statistical programming environment ([@bib15]). All subsequent data analysis procedures were also performed in R. Data were normalised using GCRMA and filtered using a variance of ⩾0.1. Differential gene expression analysis was performed using the normalised and filtered set of probes with ANOVA and eBayes. An adjusted *P*⩽0.05 after correction for multiple testing (Benjamini--Hochberg) was considered as significantly different between the two groups. Gene set enrichment analysis (GSEA) was performed as previously described using the C1, C2, C3 and C5 gene sets ([@bib44]; [@bib18]). Leading edge analysis was performed to identify the most biologically important genes within sets that were identified as differentially regulated between AK and SCC. Gene ontology (GO) was performed using the online bioinformatic tool DAVID. To assess the effect of differentiation status and immune status on the expression profile, unsupervised hierarchical clustering of the GCRMA normalised and filtered probes (*n*=22 926) was performed using Ward average linkage. A Fisher\'s exact test was used to measure the compactness of clustering for each variable.

Quantitative real-time PCR
--------------------------

Quantitative real-time PCR (qRT-PCR) was performed on an independent set of biopsies. Total RNA was extracted from fresh-frozen biopsies by homogenisation under liquid nitrogen. In total, RNA was extracted from five normal skin samples, nine AKs, nine WD SCC and 9 MD SCC using the RNeasy Mini kit with on-column DNAse digestion (Qiagen, Manchester, UK) according to the manufacturer\'s instructions. First-strand cDNA was synthesised from 500 ng RNA using Superscript III First-Strand Synthesis SuperMix, with a combination of 2.5 *μ*[M]{.smallcaps} oligo dT and random primers (2.5 ng *μ*l^−1^) (Invitrogen, Paisley, UK). cDNA was diluted 1 : 10 before real-time quantitative PCR (QPCR) analysis. Quantitative PCRs were run in triplicate on the ABI 7500 Real time PCR machine (Invitrogen) using 1 *μ*l diluted cDNA and Brilliant II SYBR Green QPCR Mastermix (Stratagene, Wokingham, UK) with the two-step cycling protocol recommended by the manufacturer. The PCR primers were intron spanning with the exception of those for *JUN*, which has a single exon (primer sequences are available in [Supplementary methods](#sup1){ref-type="supplementary-material"}). Relative expression data were calculated by the equation 2^ΔΔCt^, using the endogeneous control gene *RPS9* as the internal reference. Data were normalised to the mean Ct value from five normal (non-lesional) skin samples. For each sample, cDNA synthesis was also performed in the absence of reverse transcriptase to exclude the possibility of genomic contamination. Statistical analysis was performed using a two-tailed *t*-test, with a *P*\<0.05 considered as statistically significant.

Results
=======

Genes involved in epidermal differentiation, angiogenesis, taxis, proliferation and adhesion are differentially expressed between AK and cSCC
---------------------------------------------------------------------------------------------------------------------------------------------

To identify DEGs between AK and cSCC, expression microarray data from 30 cSCC and 10 AKs were analysed by two different statistical algorithms: ANOVA and eBayes ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). The probes that were identified as differentially expressed by both methods were considered as a robust set of DEGs between AK and cSCC (adjusted *P*\<0.05). In total, this included 239 probes (131 were upregulated in the cSCC and 108 were downregulated), which corresponded to 196 annotated genes ([Tables 2A](#tbl2a){ref-type="table"}, [2b](#tbl2b){ref-type="table"}). This probe list notably included two upregulated genes that have been consistently identified as overexpressed in cSCC from previous microarray studies (*MMP1* and *CDH3*), as well as downregulation of the differentiation-specific keratin, *KRT10*, which is also consistently reported in cSCC ([@bib48]).

Clustering of the samples using these probes revealed two main groups, one containing the majority of cSCC (20 out of 30) and the second containing the AK and remaining 10 cSCC ([Figure 1](#fig1){ref-type="fig"}). The cluster containing only cSCC included 73% (11 out of 15) of the MD--PD tumours, compared with 40% (6 out of 15) of the WD tumours, although this difference did not reach statistical significance using a two-tailed Fisher\'s exact test. There were no other significant clinical or pathological features relating to age at diagnosis, gender, immune status or tumour location (sun exposed *vs* non-sun exposed) that accounted for separation of the cSCC across the two groups. Careful laser capture microdissection of tissue samples used for RNA extraction makes it unlikely that stromal contamination was responsible for the clustering of some cSCC with the AK samples. Rather, it may indicate that there is a spectrum of tumour development. AK10 was clustered on an outlying clade within the same cluster as the other AK samples. There were no outstanding clinical or pathological features of this case (male, aged 80, immunocompetent, sun-exposed site) that accounted for its position within the clustering, again suggesting that it could represent natural variation among the samples.

To identify biological processes represented by the DEGs, GO was performed using the online bioinformatic tool, DAVID. This revealed terms associated with angiogenesis, epidermal development and differentiation, taxis, proliferation and adhesion ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). In keeping with these ontology terms, some of the genes that showed the largest fold-change downregulation in the cSCC were those involved in terminal epidermal differentiation, including filaggrin (*FLG*), filaggrin family member 2 (*FLG2*), loricrin (*LOR*) and late cornified envelope 1B (*LCE1B*). Those that were strongly upregulated in cSCC included the matrix metallopeptidases *MMP1* and *MMP10*, and a set of genes associated with migration and focal adhesion (including filamin A (*FLNA*), *FLNB*, integrin alpha 5 (*ITGA5*), jun proto-oncogene (*JUN*), met proto-oncogene, laminin-5 gamma2 chain (*LAMC2*), p21 protein (Cdc42/Rac)-activated kinase 2 (*PAK2*), vascular endothelial growth factor A (*VEGFA*) and Zyxin (*ZYX*).

qRT-PCR validates microarray differential gene expression analysis
------------------------------------------------------------------

To validate the findings of the microarray analysis, eight genes identified by both statistical methods (*ACVR2A*, *ID4*, *INHBA*, *JUN*, *MET*, *MMP10*, *PAK2* and *PTHLH*) were assessed by qRT-PCR in an independent series of 27 lesions (9 AKs, 9 WD SCC and 9 MD SCC). In addition, a further three genes that were identified by the ANOVA only were validated (*ADAM17*, *ANXA1* and *PLK1*), as well as *MAPK1* that was identified by eBayes only. In all cases, the qRT-PCR data confirmed significant upregulation or downregulation between the AK and either the WD SCC, MD SCC or combined values (WD+MD), suggesting good reliability for the genes identified by this microarray study ([Figure 2](#fig2){ref-type="fig"}).

GSEA identifies overrepresentation of members of the MAPK pathway genes in cSCC
-------------------------------------------------------------------------------

GSEA was performed to investigate the expression of genes within *a priori* established gene sets, to identify whether a group of genes that share a defined category (such as biological function, pathway or chromosomal location) show collective differences in expression between AK and cSCC. This is a useful tool for extrapolating biologically relevant information from microarray studies, and is particularly robust as it focuses on a group of genes that share a category, rather than individual genes that may be subject to signal-to-noise background. In total, 28 significantly enriched gene sets were identified (*P*⩽0.05, FDR \<0.25). These could be broadly classified into four categories: signal transduction or apoptosis, cell cycle or replication, metabolic processes or cell motility and miscellaneous (which included gene sets related to the expression profile of other cancer types) ([Table 3](#tbl3){ref-type="table"}; [Figure 3A and B](#fig3){ref-type="fig"}). Analysis of the leading edge genes underlying the enrichment of each individual gene set revealed that many were consistently represented, suggesting that they strongly influenced the expression pattern in SCC. These included multiple members of the MAPK family (including *JUN*, *FOS*, *MET*, *MAPK1*, *MAP2K2* and *MAP3K5*) and the apoptotic response (including *PAK2*, *BAX*, *DEDD*, *DAXX* and *DFFA*), suggesting that the interplay of the MAPK pathway and apoptotic response may be a critical determinant of AK to cSCC progression. No gene sets were identified from chromosomal and cytogenetic locations or conserved *cis*-regulatory motifs.

WD tumours display a distinct expression profile to MD and PD cSCC
------------------------------------------------------------------

To investigate the effect of different variables on the expression profile of the SCC, unsupervised hierarchical clustering of the cSCC only was performed. This revealed two main clusters: cluster 1 contained predominantly WD tumours and cluster 2 contained mostly MD and PD tumours ([Figure 3C](#fig3){ref-type="fig"}). The clusters show that WD tumours form the most significant cluster (*P*=0.002) with 13 out of 15 (86.7%) WD tumours in cluster 1, clearly separating them from the majority of MD and PD tumours ([Figure 3D](#fig3){ref-type="fig"}). Moderately differentiated and PD tumours themselves form weaker clusters (*P*=0.05 and *P*=0.06, respectively), however when combined they show a highly significant clustering pattern (*P*=0.002). This is in keeping with the histological heterogeneity of higher grade SCC, which often shows areas of varying differentiation rather than a consistent differentiation status across the whole tumour. Immune status showed no influence on clustering across all tumours, with around half of each status present in both clusters (*P*=0.55 for both).

Differential gene expression analysis (eBayes and ANOVA) identified no DEGs between WD cSCC and their MD/PD counterparts after correction for multiple testing, likely due to the small number of samples in each subgroup. Similarly, no genes were identified as differentially expressed between tumours from immunosuppressed *vs* immunocompetent patients (examined within the category of WD cSCC only to avoid bias from the differentiation status of the tumours).

Discussion
==========

Cutaneous SCC is the most highly mutated of all cancers, and consequently displays a complex genetic background ([@bib9]). Our study identified a set of 196 DEGs between AK and cSCC, with enrichment for genes involved in loss of differentiation (including downregulation of *FLG*, *FLG2*, *LOR*, *LCE1B*, *KRT9* and *KRT10* in cSCC), and gain of invasive properties such as extracellular matrix remodelling and cell migration. We have identified the MAPK pathway as pivotal to many of these processes, and specifically found the oncogenes *JUN* and *MET* to be overexpressed in cSCC. This is particularly significant as the contribution of oncogenes to cSCC development has remained elusive, despite the identification of a number of key tumour suppressor genes such as *TP53*, *CDKN2A* and, recently, *NOTCH* ([@bib24]; [@bib4]; [@bib9]; [@bib49]). Furthermore, we have shown that WD cSCC display a distinct expression profile to MD or PD tumours, which has implications for future targeted therapies.

Actinic keratoses represent a precancerous stage in cSCC genesis, and provide an opportunity to characterise processes relevant to the progression of skin carcinogenesis. Many previous expression microarray studies of the transition from AK to cSCC have identified few (\<10), or no, DEGs between these two disease states ([@bib32]; [@bib34]; [@bib40]). In a systematic review of six microarrays studies, it was suggested that the low consensus for differential gene expression in cSCC resulted from clinical and methodological differences, including small sample sizes, tissue processing, different baseline comparators (normal skin or AK) and varied bioinformatic approaches ([@bib48]). Importantly, the findings from our study are consistent with recently published work that combined laser capture microdissection with reverse phase protein microarray analysis ([@bib10]). This study also identified activation of the MAPK pathway in cSCC compared with AK and normal skin, highlighting the power of stringent laser capture microdissection for improved consistency across studies. In addition, a further study that focused on a smaller series of AK and cSCC from OTRs also identified the MAPK pathway to be activated in cSCC ([@bib17]). Although we cannot be sure the individual AK used across these studies had the potential to progress, the pattern of differential expression supports consistent differences in the biology of these tumours with a shift in invasive properties between AK and cSCC.

MAPK pathway in cSCC
--------------------

The oncogenes MET, JUN and PAK2 were all overexpressed in cSCC compared with AK. Both MET and JUN are direct components of the MAPK pathway, which was identified by GSEA to be a key difference between AK and cSCC. MAPK signalling has a central role in regulating growth and survival of cancer cells, and the RAF/MEK/ERK pathway is dysregulated in approximately one-third of human cancers ([@bib8]). Consequently, a number of small molecule inhibitors have been designed to target specific steps in MAPK signalling (including MET) and are now in clinical trials ([@bib47]). The potential importance of this pathway in cSCC has recently been highlighted by the rapid development of cSCC in a proportion of patients treated with the multi-kinase inhibitor, Sorafenib, or the selective BRAF V600E inhibitors, Vemurafenib and Dabrafenib ([@bib41]). There is evidence that this is caused by paradoxical activation of the MAPK pathway, which is proposed to cooperate with pre-existing somatic UV-induced mutations in key oncogenes and tumour suppressors such as *H-RAS* and *TP53* ([@bib21]; [@bib22]; [@bib36]; [@bib1]).

We also observed strong upregulation of the collagenase *MMP1* and the stromeolysin *MMP10* in cSCC, both of which are associated with invasion and metastasis *via* degradation of ECM proteins ([@bib33]). MMP1 upregulation is one of the few consistent findings across multiple cSCC microarray studies and, similar to targets in the MAPK pathway, has therapeutic potential for inhibition ([@bib48]; [@bib14]). In addition, pro-metastatic molecules such as PTHLH and osteopontin (SPP1) were upregulated in our data set, whereas putative tumour suppressors such as RORA, PDZD2 and AZGP1 were found to be downregulated ([@bib45]; [@bib51]; [@bib50]).

Transcriptome profiles reflect histological subtypes of cutaneous SCC
---------------------------------------------------------------------

Histological subtypes of cSCC are associated with distinct clinical characteristics and behaviour, with poor differentiation an independent prognostic factor for metastatic potential ([@bib31]; [@bib3]; [@bib23]). We have previously shown that WD cSCC display a distinct genetic profile to MD and PD tumours, with fewer genomic aberrations overall ([@bib37]). In addition, single gene-specific studies have reported differential expression or genomic aberration patterns between cSCC of different histological grades, including higher expression of *LRIG-1* in WD cSCC, an association of *PTPRD* deletions with PD cSCC and overexpression of Survivin in PD tumours ([@bib28]; [@bib46]; [@bib27]). Our transcriptome data support the genomic profiling by finding that WD tumours display a distinct expression profile to MD and PD cSCC. While we were unable to identify specific genes that are differentially expressed between the subgroups (most likely due to small sample numbers), our data imply that the histological subtypes of cSCC should be defined when addressing the molecular pathogenesis, prevention and treatment of these tumours.

In conclusion, our study is the first to describe widespread transcriptome changes between precancerous AK and cSCC in both immunocompetent and immunosuppressed individuals. These data highlight several known oncogenes, and reveal a broad spectrum of disrupted cellular processes that are altered in cSCC. The MAPK pathway shows pivotal changes, and offers a new approach to targeted preventative and therapeutic strategies. Finally, our data indicate that histological subtypes of cSCC represent distinct entities at the transcriptome level, and may in the future require individually tailored therapeutic approaches.
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![**Heat map of 239 overlapping differentially expressed probes identified by ANOVA and eBayes analysis of cSCC *vs* AK.** Characterisation bars beneath the dendrogram highlight key clinicopathological variables. Abbreviations: AK= actinic keratosis; IC= immunocompetent; IS= immunosuppressed; MD= moderately differentiated; PD= poorly differentiated; SCC= squamous cell carcinoma; WD= well differentiated.](bjc2013760f1){#fig1}

![**qRT-PCR analysis of 12 differentially expressed genes between AK and cSCC.** Solid black squares indicate outlier samples. For the purposes of comparison, the cSCC has been split into WD and MD categories, as well as overall values (SCC). Abbreviations: AK= actinic keratosis; MD= moderately differentiated; SCC= squamous cell carcinoma; WD= well differentiated.](bjc2013760f2){#fig2}

![**Enrichment of differences in the MAPK signalling pathway (HSA04010) between AK and cSCC as identified by GSEA, and cluster analysis of cSCC.** (**A**) Enrichment of genes in the MAPK signalling pathway. The blue line indicates the enrichment score (ES) and the black vertical lines beneath correspond to individual genes within the set, ranked according to their enrichment. If no enrichment was present, then the genes would be distributed equally from left to right. (**B**) Heat map of the enriched genes, showing their level of expression across AK and cSCC. Red indicates high expression and green indicates low expression. Each row corresponds to a gene within the MAPK gene set, while each column corresponds to an individual sample. (**C**) Cluster dendrogram revealing two main clusters of cSCC, separated predominantly by differentiation status (WD *vs* M/PD). Abbreviations: AK= actinic keratosis; IC= immunocompetent; IS= immunosuppressed; MD= moderately differentiated; PD= poorly differentiated; SCC= squamous cell carcinoma; WD= well differentiated.](bjc2013760f3){#fig3}

###### Sample characteristics

  **Sample name**   **AK/SCC**    **Patient no.**  **Differentiation status**   **Immune status**   **Gender**   **Location**    **Age (years)**
  ----------------- ------------ ----------------- ---------------------------- ------------------- ------------ -------------- -----------------
  AK1               AK                   8         NA                           IC                  M            Leg                   52
  AK2               AK                  10         NA                           IS                  M            Scalp                 65
  AK3               AK                   9         NA                           IS                  M            Hand                  69
  AK4               AK                  11         NA                           IC                  M            R hand                89
  AK5               AK                   2         NA                           IS                  F            Hand                  71
  AK6               AK                   1         NA                           IS                  M            Hand                  63
  AK7               AK                   4         NA                           IS                  M            Hand                  57
  AK8               AK                   5         NA                           IS                  M            Hand                  57
  AK9               AK                   6         NA                           IS                  M            Scalp                 72
  AK10              AK                   7         NA                           IC                  M            Hand                  80
  SCC1              SCC                  1         WD                           IS                  M            Elbow                 63
  SCC2              SCC                  2         WD                           IS                  F            Hand                  69
  SCC3              SCC                  3         WD                           IC                  M            Calf                  74
  SCC4              SCC                  4         WD                           IS                  M            Upper arm             56
  SCC5              SCC                  5         WD                           IS                  M            Hand                  49
  SCC6              SCC                  9         WD                           IS                  M            Scalp                 70
  SCC7              SCC                 10         WD                           IS                  M            Temple                64
  SCC8              SCC                 11         WD                           IC                  M            Temple                88
  SCC9              SCC                 14         WD                           IC                  M            Temple                77
  SCC10             SCC                 15         WD                           IC                  M            Pinna                 NA
  SCC11             SCC                 16         WD                           IS                  M            Neck                  30
  SCC12             SCC                 22         WD                           IS                  M            Scalp                 56
  SCC13             SCC                 23         WD                           IS                  F            Finger                47
  SCC14             SCC                 30         WD                           IC                  M            Groin                 67
  SCC15             SCC                 31         WD                           IS                  M            Forearm               46
  SCC16             SCC                  6         MD                           IS                  M            Pinna                 73
  SCC17             SCC                  8         MD                           IC                  M            Chest                 52
  SCC18             SCC                 17         MD                           IC                  M            Temple                77
  SCC19             SCC                 21         MD                           IS                  F            Shin                  66
  SCC20             SCC                 24         W-MD                         IS                  M            Pinna                 80
  SCC21             SCC                 25         MD                           IS                  M            Pinna                 58
  SCC22             SCC                 26         MD                           IS                  M            Neck                  41
  SCC23             SCC                 27         MD                           IS                  M            Chest                 51
  SCC24             SCC                 28         MD                           IC                  M            Temple                69
  SCC25             SCC                 12         M-PD                         IC                  F            Calf                  86
  SCC26             SCC                 13         M-PD                         IS                  F            Finger                59
  SCC27             SCC                 18         M-PD                         IS                  F            Foot                  73
  SCC28             SCC                 19         PD                           IS                  M            Cheek                 75
  SCC29             SCC                 20         PD                           IS                  M            Pinna                 68
  SCC30             SCC                 29         M-PD                         IS                  M            Neck                  67

Abbreviations: AK=actinic keratosis; F=female; IC=immunocompetent; IS=immunosuppressed; M=male; MD=moderately differentiated; NA=not available; PD=poorly differentiated; SCC=squamous cell carcinoma; WD=well differentiated.

###### Differentially expressed genes downregulated between AK and cSCC, as identified by both ANOVA and eBayes

  **Gene name**   **Log2 FC**   **Adj** ***P*****-value**   **Gene name**   **Log2 FC**   **Adj** ***P*****-value**
  --------------- ------------- --------------------------- --------------- ------------- ---------------------------
  *FLG2*          −6.0          2.96E−02                    *LOC283070*     −2.2          3.36E−03
  *KRT9*          −5.8          8.31E−04                    *SEPP1*         −2.1          1.57E−02
  *KRT77*         −5.4          8.31E−04                    *SERTAD4*       −2.0          1.34E−03
  *FLG*           −5.3          3.30E−02                    *GLDN*          −1.9          2.87E−02
  *LOR*           −5.2          1.73E−02                    *UBL3*          −1.9          3.34E−03
  *LCE1B*         −5.2          3.67E−02                    *LYPLAL1*       −1.9          2.41E−02
  *SERPINB12*     −5.2          1.55E−02                    *ARL5A*         −1.8          8.24E−03
  *AZGP1*         −4.9          6.23E−04                    *HNRPLL*        −1.8          3.14E−02
  *CD36*          −4.7          5.44E−04                    *BOC*           −1.8          7.15E−03
  *AADACL2*       −4.1          1.43E−02                    *GGTA1*         −1.8          2.91E−02
  *HPGD*          −3.8          3.22E−03                    *ELOVL6*        −1.7          4.14E−03
  *SERPINA12*     −3.6          4.57E−02                    *SPATA6*        −1.7          1.07E−02
  *TNFRSF19*      −3.3          4.82E−02                    *C1orf96*       −1.7          2.05E−03
  *MUC15*         −3.3          6.07E−03                    *IDE*           −1.7          1.44E−02
  *MFAP3L*        −3.3          1.63E−02                    *CREBL2*        −1.7          1.55E−03
  *ATP6V1C2*      −3.2          4.90E−03                    *PGRMC2*        −1.6          3.43E−02
  *ELOVL4*        −3.1          3.34E−03                    *KRT10*         −1.6          1.51E−02
  *BPIL2*         −3.1          3.46E−03                    *SLC30A1*       −1.6          7.91E−04
  *TGFBR3*        −3.0          5.44E−04                    *ZDHHC23*       −1.5          1.55E−02
  *EDNRB*         −2.9          1.82E−05                    *TMEM45A*       −1.5          3.36E−03
  *PDZD2*         −2.9          1.55E−03                    *ATP7A*         −1.5          1.45E−02
  *ITM2A*         −2.9          1.67E−02                    *C5orf41*       −1.5          3.86E−02
  *MARCH3*        −2.8          7.15E−03                    *KIAA1370*      −1.5          7.15E−03
  *LAMB4*         −2.8          4.69E−02                    *OLFM2*         −1.4          3.86E−02
  *EGR3*          −2.7          7.76E−03                    *PARM1*         −1.4          2.25E−02
  *ZNF682*        −2.7          1.53E−02                    *TCP11L2*       −1.4          8.24E−03
  *METTL7A*       −2.6          1.21E−03                    *SECISBP2L*     −1.3          1.64E−02
  *RORA*          −2.6          5.18E−04                    *MIPEP*         −1.3          3.66E−02
  *QPCT*          −2.5          1.19E−02                    *OXCT1*         −1.3          2.87E−02
  *LGR6*          −2.5          2.19E−02                    *ATAD2B*        −1.3          3.72E−02
  *ID4*           −2.5          3.28E−02                    *CNOT6L*        −1.2          2.32E−02
  *HLF*           −2.5          4.57E−03                    *SLC26A11*      −1.2          1.45E−02
  *GRAMD1C*       −2.4          2.35E−03                    *RNLS*          −1.2          3.01E−02
  *LONRF1*        −2.3          8.31E−04                    *ACVR2A*        −1.2          2.05E−03
  *PPM1L*         −2.3          2.20E−02                    *CEP68*         −1.2          2.05E−02
  *GLRX*          −2.2          2.43E−03                    *DYNC1LI1*      −1.1          6.22E−03
  *ITGBL1*        −2.2          2.18E−02                    *TANC1*         −1.1          1.34E−02
  *FAM13C*        −2.2          1.07E−02                    *ATG2B*         −1.1          1.21E−03
  *MATN2*         −2.2          3.13E−02                    *WDFY3*         −1.1          2.97E−02
  *CADM1*         −2.2          1.36E−02                    *KIAA1012*      −1.0          1.57E−02
  *GAS7*          −2.2          9.34E−04                    *NARG1L*        −1.0          2.57E−02
  *TRAM1L1*       −2.2          4.33E−02                                                   

Abbreviations: AK=actinic keratosis; ANOVA=analysis of variance; cSCC= cutaneous squamous cell carcinoma; FC=fold change.

###### Differentially expressed genes upregulated between AK and cSCC, as identified by both ANOVA and eBayes

  **Gene name**   **Log2 FC**   **Adj** ***P*****-value**   **Gene name**   **Log2 FC**   **Adj** ***P*****-value**
  --------------- ------------- --------------------------- --------------- ------------- ---------------------------
  *MMP1*          4.6           3.46E−02                    *CDC42BPB*      1.4           6.22E−03
  *MMP10*         4.4           3.77E−04                    *S100A6*        1.4           4.56E−02
  *CXCL1*         4.1           7.91E−04                    *IL4R*          1.4           1.33E−02
  *INHBA*         3.7           6.07E−03                    *SPATS2*        1.4           3.72E−02
  *SPP1*          3.7           7.91E−04                    *ZCCHC10*       1.4           1.33E−02
  *PTHLH*         3.5           7.81E−04                    *SRM*           1.4           4.39E−02
  *SH2D5*         3.5           2.91E−03                    *JAG1*          1.4           4.14E−02
  *ALDH1A3*       3.3           1.85E−02                    *JOSD1*         1.4           1.43E−02
  *LAMC2*         3.1           2.35E−03                    *ZYX*           1.3           2.76E−02
  *GPRC5A*        2.9           3.88E−02                    *NOLC1*         1.3           2.87E−02
  *PLAUR*         2.8           3.77E−04                    *GLT25D1*       1.3           3.03E−02
  *GPR68*         2.7           2.17E−02                    *CTSB*          1.3           2.97E−02
  *STC1*          2.3           4.33E−02                    *YKT6*          1.3           2.90E−02
  *ERO1L*         2.2           3.46E−03                    *HIST1H2BI*     1.3           2.37E−02
  *ANXA2*         2.2           1.97E−02                    *HN1L*          1.3           4.53E−02
  *MTHFD1L*       2.2           1.43E−02                    *FLNB*          1.3           2.95E−02
  *SLC16A3*       2.2           1.33E−03                    *MAP3K13*       1.3           3.75E−02
  *EIF4EBP1*      2.2           1.64E−02                    *PLEC1*         1.3           1.73E−02
  *PLAU*          2.2           6.31E−03                    *RPS6KA4*       1.3           2.05E−03
  *FLNA*          2.1           1.08E−03                    *IFRD2*         1.3           1.19E−02
  *IGF2BP2*       2.1           2.35E−03                    *ANKLE2*        1.2           2.97E−02
  *ITGA5*         2.1           8.31E−04                    *TSC2*          1.2           3.32E−02
  *HRH1*          2.1           4.20E−02                    *SLC9A1*        1.2           5.44E−04
  *KLF7*          2.1           8.19E−03                    *TES*           1.2           2.16E−02
  *FAM83A*        2.0           2.16E−02                    *LRRC8A*        1.2           3.01E−02
  *TRIP10*        2.0           7.15E−03                    *N4BP1*         1.2           6.07E−03
  *NRP2*          2.0           1.85E−02                    *DNAJC8*        1.2           7.11E−03
  *PDIA5*         2.0           2.43E−03                    *PLOD1*         1.2           1.96E−03
  *SERPINB1*      2.0           1.45E−02                    *S100A13*       1.2           2.88E−02
  *SRGAP1*        1.9           1.43E−02                    *PDXK*          1.2           3.30E−02
  *TYMP*          1.9           2.29E−02                    *TCF3*          1.1           3.34E−03
  *SESTD1*        1.8           2.88E−02                    *PVR*           1.1           3.63E−03
  *RASIP1*        1.8           1.57E−02                    *VPS72*         1.1           1.08E−02
  *C11orf17*      1.8           1.72E−02                    *PAK2*          1.1           1.22E−02
  *NOP56*         1.8           1.40E−02                    *CAD*           1.1           2.26E−02
  *C16orf57*      1.8           1.05E−02                    *RUVBL1*        1.1           4.06E−02
  *TGFA*          1.7           1.19E−02                    *TICAM1*        1.1           3.63E−03
  *MET*           1.7           5.00E−03                    *B4GALT1*       1.1           1.57E−02
  *CARHSP1*       1.7           1.05E−02                    *GPR153*        1.1           8.57E−04
  *ZAK*           1.7           5.44E−04                    *HNRNPU*        1.1           2.97E−02
  *HN1*           1.7           2.11E−02                    *ZNF697*        1.1           7.15E−03
  *FTL*           1.6           1.84E−02                    *CDC27*         1.0           1.55E−03
  *TNFRSF12A*     1.6           7.15E−03                    *MARK3*         1.0           3.52E−02
  *CDCP1*         1.6           7.66E−03                    *CEBPD*         1.0           4.02E−02
  *RFTN1*         1.6           3.30E−02                    *AP2A2*         1.0           3.34E−03
  *KLF6*          1.6           4.74E−02                    *ZBED4*         1.0           3.98E−02
  *TRIO*          1.6           4.06E−02                    *CTSLL3*        1.0           1.69E−02
  *EHD2*          1.5           4.73E−02                    *BRD9*          1.0           3.86E−02
  *TCOF1*         1.5           4.57E−02                    *SF3A2*         0.9           1.33E−03
  *NRIP3*         1.5           3.34E−03                    *HEATR2*        0.9           3.75E−02
  *CDH3*          1.5           2.60E−02                    *RFT1*          0.9           2.06E−02
  *JUN*           1.5           1.50E−02                    *SOCS1*         0.8           1.28E−02
  *CDC20*         1.5           6.14E−03                    *GTSE1*         0.8           3.77E−04
  *RRBP1*         1.5           2.17E−02                    *GALE*          0.7           2.37E−02
  *BOP1*          1.4           1.73E−02                    *ATP13A1*       0.7           4.89E−02
  *SDC4*          1.4           4.89E−02                    *VPS37B*        0.6           3.72E−02
  *VEGFA*         1.4           4.12E−02                                                   

Abbreviations: AK=actinic keratosis; ANOVA=analysis of variance; cSCC= cutaneous squamous cell carcinoma; FC=fold change.

###### **GSEA analysis**

  **GSEA category**                                            **Size**  **Source**   **ES**     **NES**   **NOM** ***P*****-value**   **FDR q-value**   **Tag %**   **Gene %**
  ----------------------------------------------------------- ---------- ------------ ---------- --------- --------------------------- ----------------- ----------- ------------
  **Signal transduction or apoptosis**                                                                                                                               
  MAPK signalling pathway                                        121     HSA04010     −0.36389   −1.5201   0.0245                      0.2425            0.322       0.176
  TNFR1 pathway                                                   20     na           −0.48995   −1.7601   0.0080                      0.1775            0.25        0.0566
  FAS pathway                                                     21     na           −0.47668   −1.6076   0.0351                      0.2479            0.381       0.156
  ST FAS signalling pathway                                       36     na           −0.61198   −2.0475   0.0000                      0.0167            0.361       0.156
  Death pathway                                                   20     na           −0.57202   −1.7337   0.0120                      0.1189            0.4         0.156
  MET pathway                                                     25     na           −0.46801   −1.5399   0.0440                      0.2416            0.4         0.181
  **Cell cycle or replication**                                                                                                                                      
  M phase                                                         65     GO:0000279   −0.62169   −1.8425   0.0197                      0.1063            0.631       0.246
  M phase of mitotic cell cycle                                   54     GO:0000087   −0.65812   −1.8475   0.0100                      0.1466            0.704       0.258
  Cell-cycle process                                             107     GO:0022402   −0.57127   −1.7439   0.0301                      0.1498            0.598       0.246
  Cell-cycle phase                                                96     GO:0022403   −0.56841   −1.7673   0.0275                      0.1550            0.583       0.246
  Mitotic cell cycle                                              92     GO:0000278   −0.59663   −1.7838   0.0235                      0.1875            0.609       0.246
  Mitosis                                                         51     GO:0007067   −0.66288   −1.865    0.0080                      0.2242            0.725       0.258
  Condensed chromosome                                            20     na           −0.61929   −1.7196   0.01536                     0.17401           0.6         0.226
  **Metabolic processes**                                                                                                                                            
  Negative regulation of cellular protein metabolic process       20     GO:0032269   −0.60511   −1.7566   0.0037                      0.1511            0.5         0.209
  Negative regulation of protein metabolic process                21     GO:0051248   −0.5716    −1.7147   0.0019                      0.1646            0.476       0.209
  Ribonucleoprotein complex                                       48     na           −0.53241   −1.7659   0.01416                     0.17705           0.583       0.275
  Pyrophosphatase activity                                        99     GO:0016462   −0.39159   −1.6548   0.0000                      0.1865            0.354       0.18
  Hydrolase activity acting on acid anhydrides                   101     GO:0016817   −0.38398   −1.6483   0.0000                      0.1689            0.347       0.18
  Nucleoside triphosphatase activity                              93     GO:0017111   −0.40821   −1.7111   0.0019                      0.2021            0.366       0.18
  Protein kinase binding                                          30     GO:0019901   −0.52176   −1.643    0.0118                      0.1559            0.3         0.113
  Pyrimidine metabolism                                           33     na           −0.55439   −1.6614   0.0196                      0.1865            0.515       0.248
  **Cell motility**                                                                                                                                                  
  Leading edge                                                    29     GO:0031252   −0.54978   −1.5753   0.0301                      0.1725            0.483       0.198
  Ruffle                                                          20     GO:0001726   −0.5811    −1.5859   0.0245                      0.1805            0.5         0.185
  Cell projection                                                 51     GO:0042995   −0.46711   −1.5155   0.0447                      0.2203            0.431       0.213
  **Miscellaneous**                                                                                                                                                  
  VHL RCC up                                                      66                  −0.51542   −1.8918   0.0000                      0.2099            0.5         0.281
  Renal cell carcinoma                                            42     HSA05211     −0.60243   −1.836    0.0000                      0.1507            0.548       0.213
  Bladder cancer                                                  30     HSA05219     −0.53204   −1.7384   0.0018                      0.2485            0.333       0.138
  Acute myeloid leukaemia                                         31     HSA05221     −0.4781    −1.5209   0.0371                      0.2498            0.323       0.138

Abbreviations: ES=enrichment score; FDR=false discovery rate; GO=gene ontology; GSEA=gene set enrichment analysis; MAPK=mitogen activated protein kinase; NES=nominal enrichment score; VHL RCC=Von Hippel-Lindau renal cell carcinoma..
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